Intimation about publication of un-audited results for quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hindustan Bio Sciences has informed BSE that its unaudited financial results for the quarter ended 30 June 2025 were published in newspapers on 2 August 2025 (Business Dairy in English and Praja Palana in Telugu), as required under SEBI LODR Regulation 47. From the published numbers, Q1 FY26 revenue stood at Rs 33.50 lakh, down from Rs 38.79 lakh in Q1 FY25, while profit after tax was Rs 1.40 lakh versus Rs 1.26 lakh in the year-ago quarter. EPS came in at Rs 0.01 on a Rs 2 face value. For full-year FY25, revenue was Rs 81.33 lakh and PAT was Rs 10.08 lakh. The results were reviewed by the Audit Committee and approved by the Board on 31 July 2025, with statutory auditors giving an unmodified opinion. The company operates only in the trading of pharmaceuticals segment.
This is a routine newspaper publication intimation rather than a fresh earnings disclosure, so no immediate price reaction is expected. However, the underlying Q1 numbers show a year-on-year revenue decline of roughly 14% with only marginal profit growth, and reserves remain negative at Rs 114.52 lakh, indicating weak financial health that small-cap investors should monitor.